Table 3.
Neoadjuvant chemoimmunotherapy-related adverse events
| Toxicity | CTCAE v5 grade | Whole population (n = 55) | Withheld pembrolizumab (n = 27) | Concomitant pembrolizumab (n = 28) | P value | ||||
|---|---|---|---|---|---|---|---|---|---|
| Before radiotherapy | Myocarditis | 2 | 1 | 1.82% | 1 | 3.7% | 0 | 0% | 1.00 |
| 3 | 7 | 12.73% | 7 | 25.93% | 0 | 0% | |||
| 4 | 0 | 0% | 0 | 0% | 0 | 0% | |||
| Ventricular dysfunction | 2 | 1 | 1.82% | 1 | 3.7% | 0 | 0% | 1.00 | |
| 3 | 3 | 5.45% | 3 | 11.11% | 0 | 0% | |||
| 4 | 0 | 0% | 0 | 0% | 0 | 0% | |||
| Cutaneous toxicity | 1 | 2 | 3.64% | 1 | 3.7% | 1 | 3.57% | 1.00 | |
| 2+ | 0 | 0% | 0 | 0% | 0 | 0% | |||
| Asthenia | 1 | 26 | 47.27% | 11 | 40.74% | 15 | 53.57% | 1.00 | |
| 2 | 1 | 1.82% | 0 | 0% | 1 | 3.57% | |||
| 3+ | 0 | 0% | 0 | 0% | 0 | 0% | |||
| Dyspnea | 1 | 2 | 3.64% | 1 | 3.7% | 1 | 3.57% | 1.00 | |
| 2 | 3 | 5.45% | 2 | 7.41% | 1 | 3.57% | |||
| 3+ | 0 | 0% | 0 | 0% | 0 | 0% | |||
| Cough | 1 | 2 | 3.64% | 1 | 3.7% | 1 | 3.57% | 1.00 | |
| 2+ | 0 | 0% | 0 | 0% | 0 | 0% | |||
| Hypothyroidy | 1 | 0 | 0% | 0 | 0% | 0 | 0% | 1.00 | |
| 2 | 6 | 10.91% | 2 | 7.41% | 4 | 14.29% | |||
| 3+ | 0 | 0% | 0 | 0 % | 0 | 0% | |||
| Hyperthyroidy | 1 | 1 | 1.82% | 1 | 3.7% | 0 | 0% | 1.00 | |
| 2 | 1 | 1.82% | 1 | 3.7% | 0 | 0% | |||
| 3 | 1 | 1.82% | 1 | 3.7% | 0 | 0% | |||
| 4 | 0 | 0% | 0 | 0% | 0 | 0% | |||
| Adrenal insufficiency | 1 | 1 | 1.82% | 0 | 0% | 1 | 3.57% | .33 | |
| 2 | 5 | 9.09% | 4 | 14.81% | 1 | 3.57% | |||
| 3+ | 0 | 0% | 0 | 0% | 0 | 0% | |||
| Other toxicity | All grades | 18 | 32.73% | 12 | 44.44% | 6 | 21.43% | ||
Abbreviation: CTCAE = Common Terminology Criteria for Adverse Events.